- Trials with a EudraCT protocol (74)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
74 result(s) found for: Mild-to-moderate Alzheimer's Disease AND ALZHEIMER Disease AND MRI.
Displaying page 4 of 4.
EudraCT Number: 2011-000914-21 | Sponsor Protocol Number: 161003 | Start Date*: 2012-02-13 | |||||||||||
Sponsor Name:Baxter Innovations GmbH | |||||||||||||
Full Title: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFECTIVENESS OF IMMUNE GLOBULIN INTRAVENOUS (HUMAN), 10% SOLUTION (IGIV, 10%) FOR THE TREATMENT OF MILD TO MODERATE A... | |||||||||||||
Medical condition: Mild to moderate Alzheimer’s disease (AD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-004120-12 | Sponsor Protocol Number: AAB-001-202 | Start Date*: 2005-05-27 | |||||||||||
Sponsor Name:Elan Pharma Ltd | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability, and Amyloid-Imaging Positron Emission Tomography (PET) Trial of AAB-001 (ELN116727) in Pa... | |||||||||||||
Medical condition: Alzheimer’s Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) FI (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-005001-29 | Sponsor Protocol Number: ZEN-006-Z030 | Start Date*: 2006-05-09 |
Sponsor Name:Zentaris GmbH | ||
Full Title: Efficacy and safety of ozarelix acetate, a new GnRH antagonist in male patients with mild to moderate Alzheimer’s Disease (Regimen: 130 mg q4w, x3) | ||
Medical condition: Male patients with mild to moderate Alzheimer´ Disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2007-005995-14 | Sponsor Protocol Number: 3133K1-3001-WW(B2521002) | Start Date*: 2009-05-29 | |||||||||||
Sponsor Name:Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola road, Collegeville, PA 19426 USA | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disea... | |||||||||||||
Medical condition: Alzheimer Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IE (Prematurely Ended) BE (Prematurely Ended) DE (Prematurely Ended) FR (Completed) FI (Prematurely Ended) SE (Prematurely Ended) IT (Prematurely Ended) PT (Prematurely Ended) AT (Prematurely Ended) NL (Prematurely Ended) DK (Prematurely Ended) ES (Prematurely Ended) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003891-11 | Sponsor Protocol Number: LMT-01-02-18 | Start Date*: 2019-07-16 | |||||||||||
Sponsor Name:Life Molecular Imaging SA | |||||||||||||
Full Title: An Open Label, Single Center Study, to evaluate the Safety and Imaging Characteristics of [18F]PI-2620 as PET Radioligand for Imaging Tau deposition in the brains of subjects with amnestic mild cog... | |||||||||||||
Medical condition: Alzheimer's Disease Amnestic Mild Cognitive Impairment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000089-11 | Sponsor Protocol Number: AX-CL-09 | Start Date*: 2004-12-15 |
Sponsor Name:Axonyx Inc | ||
Full Title: A randomised, double-blind, placebo-controlled study to evaluate the safety and efficacy of two different doses of phenserine-tartrate in patients with probable mild to moderate Alzheimer’s disease | ||
Medical condition: Alzheimer's Disease is caused by a loss of nerve cells in the brain, particularly in the areas associated with memory and learning. The onset of Alzheimer's also affects the levels of a certain neu... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Completed) AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-001616-45 | Sponsor Protocol Number: IG0502 | Start Date*: 2005-07-22 |
Sponsor Name:Instituto Grifols S.A. | ||
Full Title: ESTUDIO PILOTO PARA EVALUAR LA EFICACIA Y SEGURIDAD DEL RECAMBIO PLASMÁTICO CON ALBÚMINA HUMANA 5% EN EL ACLARAMIENTO PERIFÉRICO DEL PEPTIDO BETA-AMILOIDE, Y SUS EFECTOS EN PACIENTES CON ENFERMEDAD... | ||
Medical condition: Alzheimer's disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-002744-25 | Sponsor Protocol Number: RK100.1 | Start Date*: 2006-06-29 |
Sponsor Name:Roskamp Institute | ||
Full Title: An open label evaluation of the safety and efficacy of nilvadipine in mild to moderate Alzheimer's Disease | ||
Medical condition: Alzheimer's disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2004-002007-33 | Sponsor Protocol Number: A2581078 | Start Date*: 2004-11-25 |
Sponsor Name:Pfizer Inc. | ||
Full Title: An 80-week, randomized, multi center, parallel group, double-blind study of the efficacy and safety of atorvastatin 80 mg plus an acetylcholinesterase inhibitor versus an acetylcholinesterase inhib... | ||
Medical condition: Alzheimer Disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-000933-12 | Sponsor Protocol Number: AX-CL-10 | Start Date*: 2005-02-22 |
Sponsor Name:Axonyx Inc | ||
Full Title: A randomised, double-blind, placebo-controlled study to evaluate the safety and efficacy of two different doses of phenserine-tartrate in patients with probable mild to moderate Alzheimer’s disease | ||
Medical condition: Alzheimers disease is caused by a loss of nerve cells in the brain, particularly in the areas associated with memory and learning. The onset of Alzheimers's also affects the levels of a certain neu... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2009-014388-38 | Sponsor Protocol Number: NEUAZ1 | Start Date*: 2009-09-28 | |||||||||||
Sponsor Name:Neurim Pharmaceuticals Ltd | |||||||||||||
Full Title: A double-blind, parallel group, randomized, placebo controlled study of the efficacy of Circadin® 2mg in alleviating sleep disturbances in patients with mild to moderate Alzheimer Disease (AD) tre... | |||||||||||||
Medical condition: Insomnia in patients with mild to moderate Alzheimers Disease. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000016-10 | Sponsor Protocol Number: 3098A1-201-EU | Start Date*: 2004-10-12 |
Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development | ||
Full Title: A 3-MONTH, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, MULTICENTER, SAFETY, TOLERABILITY, AND EFFICACY STUDY OF 3 DOSES OF SRA-333 IN OUTPATIENTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE WITH ... | ||
Medical condition: Alzheimer's Disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FI (Completed) SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-000163-89 | Sponsor Protocol Number: COG0104 | Start Date*: 2018-04-23 | |||||||||||
Sponsor Name:Cognition Therapeutics, Inc. | |||||||||||||
Full Title: A Pilot Study to Evaluate the Effect of CT1812 Treatment on Aβ Oligomer Displacement into CSF in Subjects with Mild to Moderate Alzheimer's Disease Followed by a Six-Month Open Label Extension of a... | |||||||||||||
Medical condition: Sponsor is developing an oral formulation of CT1812 fumarate to treat AD and mild cognitive impairment. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-007134-19 | Sponsor Protocol Number: GAM10-04 | Start Date*: 2009-01-14 |
Sponsor Name:Octapharma AG | ||
Full Title: Prospective 24-week, double-blind, randomized, placebo-controlled, multicenter study evaluating safety and change in efficacy-related surrogate parameters in patients with dementia of the Alzheimer... | ||
Medical condition: mild to moderate Alzheimer´s disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
